Patents by Inventor Yanping Xu

Yanping Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7998999
    Abstract: The present invention discloses novel compounds of Formula I: having 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11?-HSD type 1 activity.
    Type: Grant
    Filed: April 24, 2007
    Date of Patent: August 16, 2011
    Assignee: Eli Lilly and Company
    Inventors: Owen Brendan Wallace, Yanping Xu, Nancy June Snyder, Jeremy Schulenburg York, Alexei Pavlovych Krasutsky
  • Patent number: 7994176
    Abstract: The present invention discloses novel compounds of Formula I: having 11 Beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11 Beta-HSD type 1 activity.
    Type: Grant
    Filed: April 24, 2007
    Date of Patent: August 9, 2011
    Assignee: Eli Lilly and Company
    Inventors: Renhua Li, Thomas Edward Mabry, Owen Brendan Wallace, Leonard Larry Winneroski, Jr., Yanping Xu
  • Patent number: 7981918
    Abstract: The present invention discloses novel compounds of Formula (I): having 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I), as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11?-HSD type 1 activity.
    Type: Grant
    Filed: April 5, 2007
    Date of Patent: July 19, 2011
    Assignee: Eli Lilly and Company
    Inventors: Thomas Daniel Aicher, Peter Biagio Anzeveno, Renhua Li, Alexei Pavlovych Krasutsky, Thomas Edward Mabry, Ashraf Saeed, Nancy June Snyder, Hongqi Tian, Owen Brendan Wallace, Leonard Larry Winneroski, Yanping Xu
  • Patent number: 7968585
    Abstract: The present invention discloses novel compounds of Formula (I): having 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11?-HSD type 1 activity.
    Type: Grant
    Filed: April 25, 2007
    Date of Patent: June 28, 2011
    Assignee: Eli Lilly and Company
    Inventors: Thomas Edward Mabry, Owen Brendan Wallace, Yanping Xu, Nancy June Snyder, Leonard Larry Winneroski, Jr.
  • Patent number: 7829582
    Abstract: The present invention discloses novel compounds of Formula I: having 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11?-HSD type 1 activity.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: November 9, 2010
    Assignee: Eli Lilly and Company
    Inventors: Owen Brendan Wallace, Yanping Xu, Jeremy Schulenburg York
  • Patent number: 7820659
    Abstract: The present invention discloses novel compounds of Formula I: (I) having 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11?-HSD type 1 activity.
    Type: Grant
    Filed: April 19, 2007
    Date of Patent: October 26, 2010
    Assignee: Eli Lilly and Company
    Inventors: Ashraf Saeed, Owen Brendan Wallace, Yanping Xu, Thomas Edward Mabry, Rebecca Lynn Rezac Guenther, Nancy June Snyder
  • Patent number: 7816349
    Abstract: The present invention discloses novel compounds of Formula I: (I) possessing 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11?-HSD type 1 activity.
    Type: Grant
    Filed: April 23, 2007
    Date of Patent: October 19, 2010
    Assignee: Eli Lilly and Company
    Inventors: John Gordon Allen, Alexei Pavlovych Krasutsky, Owen Brendan Wallace, Yanping Xu, Jeremy Schulenburg York
  • Patent number: 7655641
    Abstract: The present invention is directed to a compound of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: February 2, 2010
    Assignee: Eli Lilly and Company
    Inventors: Scott Eugene Conner, Lynn Stacy Gossett, Jonathan Edward Green, Winton Dennis Jones, Jr., Nathan Bryan Mantlo, Donald Paul Matthews, Daniel Ray Mayhugh, Daryl Lynn Smith, Jennifer Ann Vance, Xiaodong Wang, Alan M Warshawsky, Leonard Larry Winneroski, Jr., Yanping Xu, Guoxin Zhu
  • Publication number: 20090275613
    Abstract: The present invention discloses novel compounds of Formula I: (I) possessing 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11?-HSD type 1 activity.
    Type: Application
    Filed: April 25, 2007
    Publication date: November 5, 2009
    Applicant: Eli Lilly and Company
    Inventors: Renhua Li, Owen Brendan Wallace, Yanping Xu
  • Patent number: 7608639
    Abstract: The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR), such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.
    Type: Grant
    Filed: October 8, 2004
    Date of Patent: October 27, 2009
    Assignee: Eli Lilly and Company
    Inventors: Leonard Larry Winneroski, Jr., Yanping Xu, Jeremy Schulenburg York
  • Publication number: 20090239911
    Abstract: The present invention discloses novel compounds of Formula I: having 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11?-HSD type 1 activity.
    Type: Application
    Filed: April 24, 2007
    Publication date: September 24, 2009
    Inventors: Owen Brendan Wallace, Yanping Xu, Nancy June Snyder, Jeremy Schulenburg York, Alexei Pavlovych Krasutsky
  • Publication number: 20090156571
    Abstract: The present invention discloses novel compounds of Formula I: possessing 11 ?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 ?-HSD type 1 activity.
    Type: Application
    Filed: April 19, 2007
    Publication date: June 18, 2009
    Inventors: Thomas Daniel Aicher, Zhaogen Chen, Ronald Jay Hinklin, Gary Alan Hite, Alexei Pavlovych Krasutsky, Renhua Li, Jefferson Ray McCowan, Ashraf Saeed, Nancy June Snyder, James Lee Toth, Owen Brendan Wallace, Leonard Larry Winneroski, Jr., Yanping Xu, Jeremy Schulenburg York
  • Patent number: 7544812
    Abstract: The present invention is directed to compounds represented by the following structural Formula (I), (a) R1 is selected from the group consisting of hydrogen, substituted or unsubstituted group selected from C1-C8 alkyl, aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, C3-C6 cycloalkylaryl-C0-2-alkyl, and —CH2—C(O)—R17-R18, wherein R17 is O or NH and R18 is optionally substituted benzyl; (b) R2 is selected from the group consisting of C1-C6 alkyl, C1-C6 alkenyl, aryl-C0-4-alkyl, heteroaryl-C0-4-alkyl, C1-C4 alkyl sulfonamide, C1-C4 alkyl amide, OR10 and C3-C6 cycloalkyl; (c) W is O or S; (d) X is an optionally substituted C1-C5 alkylene linker wherein one carbon atom of the linker may optionally be replaced with O, NH, S, and optionally two carbons together may form a double bond; (e) Y is selected from the group consisting of C, O, S, NH and a single bond; and (f) E is selected from the group consisting of C(R3)(R4)A, A, and a substituted or unsubstituted group selected from the group consisting of (CH2)n COOR19.
    Type: Grant
    Filed: November 26, 2002
    Date of Patent: June 9, 2009
    Assignee: Eli Lilly and Company
    Inventors: Tracey Ann Gibson, Richard Duane Johnston, Nathan Bryan Mantlo, Richard Craig Thompson, Leonard Larry Winneroski, Yanping Xu, Xiaodong Wang
  • Publication number: 20090111809
    Abstract: The present invention discloses novel compounds of Formula I: (I) having 11-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11-HSD type 1 activity.
    Type: Application
    Filed: April 23, 2007
    Publication date: April 30, 2009
    Inventors: Julie Kay Bush, Marvin Martin Hansen, Renhua Li, Thomas Edward Mabry, Nancy June Snyder, Owen Brendan Wallace, Yanping Xu
  • Publication number: 20090111800
    Abstract: The present invention discloses novel compounds of Formula (I): having 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I), as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11?-HSD type 1 activity.
    Type: Application
    Filed: April 5, 2007
    Publication date: April 30, 2009
    Inventors: Thomas Daniel Aicher, Peter Biagio Anzeveno, Renhua Li, Alexei Pavlovych Krasutsky, Thomas Edward Mabry, Ashraf Saeed, Nancy June Snyder, Gregory Alan Stephenson, Hongqi Tian, Owen Brendan Wallace, Leonard Larry Winneroski, JR., Yanping Xu
  • Publication number: 20090099182
    Abstract: The present invention discloses novel compounds of Formula I: having 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11?-HSD type 1 activity.
    Type: Application
    Filed: April 24, 2007
    Publication date: April 16, 2009
    Inventors: Renhua Li, Thomas Edward Mabry, Owen Brendan Wallace, Leonard Larry Winneroski, JR., Yanping Xu
  • Publication number: 20090099180
    Abstract: The present invention discloses novel compounds of Formula (I): having 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11?-HSD type 1 activity.
    Type: Application
    Filed: April 25, 2007
    Publication date: April 16, 2009
    Inventors: Thomas Edward Mabry, Owen Brendan Wallace, Yanping Xu, Nancy June Snyder, Leonard Larry Winneroski, JR.
  • Publication number: 20090088430
    Abstract: The present invention discloses novel compounds of Formula I: having 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11?-HSD type 1 activity.
    Type: Application
    Filed: April 27, 2007
    Publication date: April 2, 2009
    Inventors: Owen Brendan Wallace, Yanping Xu, Jeremy Schulenburg York
  • Publication number: 20090088428
    Abstract: The present invention discloses novel compounds of Formula I: (I) having 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11?-HSD type 1 activity.
    Type: Application
    Filed: April 19, 2007
    Publication date: April 2, 2009
    Inventors: Ashraf Saeed, Owen Brendan Wallace, Yanping Xu, Thomas Edward Mabry, Rebecca Lynn Rezac Guenther, Nancy June Snyder
  • Publication number: 20090069326
    Abstract: The present invention discloses novel compounds of Formula I: (I) possessing 11?-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11?-HSD type 1 activity.
    Type: Application
    Filed: April 23, 2007
    Publication date: March 12, 2009
    Inventors: John Gordon Allen, Alexei Pavlovych Krasutsky, Owen Brendan Wallace, Yanping Xu, Jeremy Schulenburg York